PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Presentations highlight two-year Phase 3 data and real-world evidence for BESREMi® (ropeginterferon alfa-2b) in essential thrombocythemia (ET)
BESREMi was recently FDA-approved for the treatment of adults with ET, regardless of genotype or disease status
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced two poster presentations at the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting, which will be held September 9-12 in Houston, Texas.
PharmaEssentia will present two-year results from the Phase 3 SURPASS-ET study (NCT04285086) and its ongoing extension in adults with high-risk essential thrombocythemia (ET) who were resistant to or intolerant of hydroxyurea. In the extension, it was observed that study participants who continued BESREMi® (ropeginterferon alfa-2b-njft) maintained modified ELN response rates and platelet and white blood cell control through two years, with continued reduction in JAK2V617F variant allele burden and a safety profile consistent with prior reports. Patients followed in the extension study who transitioned from anagrelide to BESREMi after the 52-week core study showed improved hematologic control and reduced JAK2V617F allele burden relative to their prior anagrelide therapy. Long-term efficacy and safety analyses are ongoing. Two-year results were presented in part as an oral presentation at the European Hematology Association (EHA) 2026 Congress.
